Business Description
BioGaia AB
ISIN : US09072J1025
Share Class Description:
BIOGY: ADRCompare
Compare
Traded in other countries / regions
BIOG B.Sweden0GTN.UKBIOGY.USABGLA.Germany IPO Date
2013-04-03Description
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.87 | |||||
| Interest Coverage | 545.44 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 26.5 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.3 | |||||
| 3-Year EBITDA Growth Rate | 20.7 | |||||
| 3-Year EPS without NRI Growth Rate | 22.9 | |||||
| 3-Year FCF Growth Rate | 17.6 | |||||
| 3-Year Book Growth Rate | 5.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.69 | |||||
| 9-Day RSI | 6.02 | |||||
| 14-Day RSI | 14.14 | |||||
| 6-1 Month Momentum % | 36.76 | |||||
| 12-1 Month Momentum % | 44.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.58 | |||||
| Quick Ratio | 8.65 | |||||
| Cash Ratio | 7.89 | |||||
| Days Inventory | 170.76 | |||||
| Days Sales Outstanding | 33.3 | |||||
| Days Payable | 42.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.88 | |||||
| Dividend Payout Ratio | 0.83 | |||||
| 3-Year Dividend Growth Rate | 24.6 | |||||
| Forward Dividend Yield % | 2.88 | |||||
| 5-Year Yield-on-Cost % | 2.32 | |||||
| Shareholder Yield % | 1.21 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.29 | |||||
| Operating Margin % | 34.03 | |||||
| Net Margin % | 28.18 | |||||
| FCF Margin % | 28.99 | |||||
| ROE % | 18.34 | |||||
| ROA % | 16.12 | |||||
| ROIC % | 45.73 | |||||
| ROC (Joel Greenblatt) % | 144.9 | |||||
| ROCE % | 22.69 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.92 | |||||
| PE Ratio without NRI | 32.92 | |||||
| Shiller PE Ratio | 42.25 | |||||
| Price-to-Owner-Earnings | 33.04 | |||||
| PEG Ratio | 3.23 | |||||
| PS Ratio | 9.31 | |||||
| PB Ratio | 5.94 | |||||
| Price-to-Tangible-Book | 6.66 | |||||
| Price-to-Free-Cash-Flow | 32.18 | |||||
| Price-to-Operating-Cash-Flow | 28.48 | |||||
| EV-to-EBIT | 22.41 | |||||
| EV-to-EBITDA | 21.26 | |||||
| EV-to-Revenue | 8.12 | |||||
| EV-to-FCF | 28.06 | |||||
| Price-to-Projected-FCF | 2.75 | |||||
| Price-to-DCF (Earnings Based) | 1.41 | |||||
| Price-to-DCF (FCF Based) | 1.11 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.08 | |||||
| Price-to-Graham-Number | 3.12 | |||||
| Price-to-Net-Current-Asset-Value | 7.65 | |||||
| Price-to-Net-Cash | 9.72 | |||||
| Earnings Yield (Greenblatt) % | 4.46 | |||||
| FCF Yield % | 3.11 | |||||
| Forward Rate of Return (Yacktman) % | 12.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIOGY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioGaia AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 121.88 | ||
| EPS (TTM) ($) | 0.34 | ||
| Beta | 0.35 | ||
| Volatility % | 31.25 | ||
| 14-Day RSI | 14.14 | ||
| 14-Day ATR ($) | 0.146995 | ||
| 20-Day SMA ($) | 11.4975 | ||
| 12-1 Month Momentum % | 44.27 | ||
| 52-Week Range ($) | 8.38 - 12.09 | ||
| Shares Outstanding (Mil) | 100.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioGaia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioGaia AB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioGaia AB Frequently Asked Questions
What is BioGaia AB(BIOGY)'s stock price today?
The current price of BIOGY is $9.72. The 52 week high of BIOGY is $12.09 and 52 week low is $8.38.
When is next earnings date of BioGaia AB(BIOGY)?
The next earnings date of BioGaia AB(BIOGY) is 2024-05-07.
Does BioGaia AB(BIOGY) pay dividends? If so, how much?
The Dividend Yield %  of BioGaia AB(BIOGY) is 2.88% (As of Today), Highest Dividend Payout Ratio of BioGaia AB(BIOGY) was 0.83. The lowest was 0.24. And the median was 0.38. The  Forward Dividend Yield % of BioGaia AB(BIOGY) is 2.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers